After Purdue inked its multibillion-dollar opioid settlement, market watchers thought other companies would face more pressure to reach their own deals. But now several are considering joining in on that deal, WSJ reports, although at this stage it remains an
read moreThe report found that there is still significant “room for improvement to promote understanding of all cancers and their risk factors.” More: Survey reveals women with cancer feel ‘stigmatised’ Source: News
read moreThe drug improved progression-free survival time to a median of 22.1 months, compared to 16.6 months. More: Continued success for Lynparza in ovarian cancer Source: News
read moreThe drug more than doubled median radiographic progression-free survival. More: Lynparza bags positive prostate cancer results Source: News
read moreThe treatment has been approved to reduce the risk of hospitalisation for heart failure in certain patients with type II diabetes. More: Invokana bags FDA approval Source: News
read moreGlaxoSmithKline’s Nucala is facing an uphill climb in its battle for supremacy in severe asthma. On the hunt for a leg up, GSK is looking to real-world studies for a competitive advantage in Nucala’s sole indication—and it may have just
read more© 1994 - 2026 B.M. Pharmaceuticals